Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoic acid in CIDP
NCT00962429Phase 2Completed
- Sponsor
- Oregon Health & Science University
- Start
- Feb 2009
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha-lipoic acid in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Oregon Health & Science University. Primary endpoint: Muscle Strength at 16 weeks. Started Feb 2009; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT00962429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962429.